Post-prandial gastrointestinal symptoms such as diarrhea, abdominal distension, flatulence, bloating and a feeling of fullness are common complaints of often unknown etiology and pathogenesis. There is a long history of trials reporting the successful use of products containing a variety of combinations of digestive enzymes including a number of randomized placebocontrolled trials. We provide a narrative review of studies describing the use of multi-digestive enzymes for symptoms consistent with irritable bowel syndrome. We describe clinical trials reported over the past 60 years including double-blinded randomized, placebo-controlled studies and recent trials that focused on post-prandial diarrhea consistent with diarrheapredominant irritable bowel syndrome. Disaccharidase deficiencies or deficiencies of other carbohydrate digesting enzymes were excluded. Worldwide studies have generally reported success with multi-enzyme preparations although none used a factorial design to identify subgroups or attempted to link specific symptom responses to specific components of therapy.
| INTRODUCTION
Post-prandial gastrointestinal symptoms or post-prandial distress or diarrhea have long been a cause of suffering and have typically been ascribed to dietary indiscretion such as the type, temperature, volume and rate of food ingestion. This is coupled with the notion that these symptoms are somehow linked to an individual's inability to digest some foods. The concept of poor digestion underlies the widespread use, availability and proliferation of digestive aids such as herbal remedies and liqueurs (e.g., Mirto™, a Sardinian digestive liqueur). People have long sought digestive aids in the belief that they provide as yet unidentified missing ingredients that promote discomfort-free digestion. More recently, the tendency has been to prescribe elimination diets, which have shown some benefits. 1 Although there are descriptions of pancreatic dysfunction in elderly patients and those with celiac disease, Crohn's disease and diabetes, there are few objective data on the benefits of pancreatic enzymes for treating such patients. 2 Interest has recently been renewed over the use of enzymes with symptoms consistent with meal-associated irritable bowel syndrome, especially those with the diarrhea-predominant irritable bowel syndrome (IBS-D). [3] [4] [5] Here, we review the three groups of patients who may benefit from enzyme therapy, i.e., those with foregut irritable bowel syndrome-like symptoms, those with meal-associated dyspepsia (e.g., abdominal distension, belching, abdominal pain, abdominal distension and epigastric burning) and those with IBS-D-like symptoms.
We exclude those with well-recognized conditions such as deficiencies of disaccharidases or other carbohydrate-digesting enzymes (e.g., lactase, trehalase and sucrase-isomaltase) which may have a similar presentation. The role of acquired mucosal disaccharidase deficiencies is still relatively uninvestigated and further studies are warranted. 6, 7 Most of the patients we describe would be classified as having functional bowel syndrome using the Rome IV criteria. 8 With an estimated global prevalence of 11.2%, functional bowel syndromes are common, which results in many patients seeking medical help because of these symptoms. 9 The Rome IV classification defines irritable bowel syndrome as "recurrent abdominal pain, on average, at least 1 day/ week in the last 3 months associated with two or more of the following criteria: related to defecation, associated with a change in frequency of stool, and associated with a change in form (appearance) of stool." 8 The Rome criteria are designed to identify specific subgroups so that those with similar characteristics can be studied. The classification is based on phenotypical criteria and many Rome criteria have been validated with "validated" meaning that when patients with the defined criteria are seen there is a high probability that most practitioners would agree that they had been categorized correctly. Phenotypical criteria lump together conditions based on superficial characteristics without any claim to provide an etiological separation, and thus the diagnosis can never be accurate in the terms of etiology or pathophysiology. One goal of using the Rome criteria is to identify groups of patients with specific characteristics that allow further differentiation, eventually leading to the enteropathogenesis and a specific therapy without excessive and unfruitful diagnostic testing. Because they are concentration-dependent, the results are often inaccurate when unformed stools are tested. 16 Clinical interpretation depends on the pretest probability. A retrospective review of over 3000 patients meeting the Rome III criteria for irritable bowel syndrome found low fecal elastase level, with a frequency of 5% to 13%. 15 Talley et al examined fecal elastase-1 levels in those with IBS-D and found abnormal levels in only 4.6%. 17 A recent review and meta-analysis of fecal elastase testing in the diagnosis of exocrine pancreatic insufficiency concluded that the false-negative rate was 1.1% and the false-positive rate was 11%. 18 In a low pretest probability condition such as IBS-D, most positive tests are likely to be false positive, especially when the stool tested is not formed.
16,18
Tests of pancreatic function other than fecal elastase-1 have been studied in patients with irritable bowel syndrome-like symptoms. One recent study suggested that the post-prandial symptoms felt in the lower part of the epigastrium were associated with a urinary test of pancreatic insufficiency measured by low urinary excretion of paraaminobenzoic acid (PABA). 19 Values below 70% excretion were found in 71.4% of those with post-prandial epigastric fullness, 69.6% of those with epigastric pain and 81.3% of those with diarrhea. No patient had abnormal abdominal X-ray examination, computed tomography or ultrasonography suggestive of chronic pancreatitis. Importantly, there was no control group and the N-benzoyl-L-tyrosyl-paminobenzoic acid (BT-PABA) test is known to have a high falsepositive rate. 20 However, it is interesting that BT-PABA test results have been shown to correlate with cine-dynamic magnetic resonance cholangiopancreatography in relation to the distance and frequency of pancreatic juice discharge (see below). 21 
| RESULTS OF ORAL ENZYME THERAPY
Most published studies of post-prandial irritable bowel syndrome-like syndromes have used oral therapy with combination products that contain pancreatic enzymes and other ingredients thought to possibly improve digestion of difficult-to-hydrolyze substances (e.g., hemicellulase and lactase). An example of a typical early study was entitled "The use of bile acids and pancreatic enzyme substitute in the treatment of 'functional indigestion'" and involved 32 patients. 22 The digestive aid used contained pancreatic enzymes, bile salts, betaine hydrochloride (a gastric acid supplement) and hemicellulase. 24 Another example is a study with a dual-layer tablet, Combizym (Daiichi-Sankyo Europe, Germany), which has an outside layer containing an extract of Aspergillus oryzae with cellulase, protease and amylase activity and an inner core of pancreatin. 25 The study was a randomized and placebo-controlled crossover study with 151 patients. The authors reported that the active product was statistically superior to a placebo for abdominal distension, belching, diarrhea, abdominal pain and epigastric burning, but not for constipation.
This result was consistent with early studies of the same product. 1, 24, 26, 27 No studies have been performed to identify which components were likely to be responsible for the treatment success.
| MEAL-ASSOCIATED DIARRHEA OR IBS-D-LIKE SYNDROMES AND PANCREATIC ENZYME THERAPY
The association of low fecal elastase level and IBS-D-like presentation has prompted therapeutic trials with pancreatic and other enzymes. The patient's symptoms were clearly related to food triggers (Tables 1   and 2 ). She had a minimally increased fecal fat (i.e., normal was defined as <7 g/24 h) as her fecal fat excretion during meals with food triggers was 10 g/24 h with IBS-D, 7.5 g/24 h with food triggers and supplemental enzyme use, and 8.8 g/24 h with no food triggers. 5 The authors also performed a pilot study of 49 patients with postprandial diarrhea with known food triggers who were randomized to placebo or pancrealipase (uncoated Viokase containing lipase 8000 USP, amylase 30 000 USP and protease 30 000 USP; Axcan Pharma). 28 The therapy could be titrated up by the patient from one to three capsules taken before consuming known trigger meals, defined as meals reliably associated with urgent post-prandial diarrhea. Pancreatic enzyme therapy resulted in the significant relief of cramping, bloating, borborygmus, nausea, number of stools and urgency to defecate compared with placebo.
28
A fecal elastase-1 level of <200 μg/g stool was found in four (6.7%) of 60 stool samples tested. The lowest was 112 μg/g stool.
Overall, 61% of the patients (P = 0.078) chose pancrelipase as the effective agent. Interestingly, three of the four with low fecal elastase-1 chose the placebo. 28 As previously noted, low fecal elastase-1, especially in low pretest probability groups, has a high false-positive rate (i.e., "in low pretest probability conditions such as irritable bowel syndrome with diarrhea one should expect a high false-positive rate"). 18 Possibly, the combination of low fecal elastase- toms. After a median of 3.7 years half patients were still using this enzyme therapy on demand. 28 Subsequently, the authors have continued to suggest this treatment as the first-line therapy for individuals who experience more frequent stools, including diarrhea, after eating, whether pain is present or not and they report substantial improvement for most.
As described above, a number of studies including double-blinded placebo-controlled studies report a beneficial effect of oral enzyme Fats and carbohydrates in modern diets have continued to change as highly processed foods occupy an increasing proportion of our diet.
For example, trehalose has become an increasing component of the diet, especially in processed and fast foods. 32 The prevalence of trehalase insufficiency is presumed to be low in human beings and their microbiomes have not been subjected to high amounts of it in the past. 33 Major sources of carbohydrates and fats include high fructose corn syrup and palm oil, which are indigestible and must be highly processed before being added to foods. 34 
| RECOMMENDATIONS FOR FUTURE STUDIES
We recommend that future studies attempt to identify specific symptoms or groups of symptoms that respond reliably to specific therapies and can be confirmed in randomized double-blinded trials. Then, factorial designs may be used to isolate and identify the important factors that may be responsible for the relief of a specific symptom or group of symptoms. Similarly, studies of the prevalence of putative biomarkers are of limited value unless they can be reliably linked to a pathophysiological or treatable condition. Fecal elastase-1 is a good example. Data that are typically lacking are whether the stools were likely to respond to enteric-coated pancreatin than patients with a similar presentation and a normal fecal elastase-1 level. 4 Ran et al tested a combination product containing an extract of
Aspergillus oryzae with cellulase, protease and amylase activity along with an inner core of pancreatin 25 and found it relieved abdominal distension, belching, diarrhea, abdominal pain and epigastric burning, but not constipation. Studies in which the symptoms are grouped (e.g., abdominal distension and belching only) are needed to define groups for subsequent study. The principle of the Rome criteria is to try to identify precisely subgroups for study and we may possibly start by using the Rome criteria and then proceed, Center.
